trending Market Intelligence /marketintelligence/en/news-insights/trending/MhHtpDcjxyngkL7ZJ7pGEQ2 content esgSubNav
In This List

OncoMed Pharmaceuticals CEO resigns

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


OncoMed Pharmaceuticals CEO resigns

Paul Hastings resigned as CEO, president, board chairman and director of OncoMed Pharmaceuticals Inc., effective Jan 1.

Hastings, who had joined OncoMed as CEO in 2006, resigned to pursue new career opportunities.

OncoMed said its board has retained an executive search firm and has initiated a search for a fulltime successor.

In the interim, the office of the president, comprising John Lewicki, executive vice president of research and development, and Sunil Patel, executive vice president and CFO, will continue to perform the duties of president and CEO.

OncoMed's board has appointed Perry Karsen as chairman, while Jack Lasersohn, formerly lead director, remains a board member.